These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 36434554)

  • 1. TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma.
    Coquan E; Clarisse B; Lequesne J; Brachet PE; Nevière Z; Meriaux E; Bonnet I; Castera M; Goardon N; Boutrois J; Travers R; Joly F; Grellard JM; Thiery-Vuillemin A
    BMC Cancer; 2022 Nov; 22(1):1213. PubMed ID: 36434554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis.
    Lee JL; Desai C; Park SH; Tsuchiya N; Su PJ; Chan TTW; Gurney H; Gao S; Wang J; Sandner R; di Pietro A; Eto M
    Urol Oncol; 2023 May; 41(5):256.e17-256.e25. PubMed ID: 37019764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The JAVELIN Bladder Medley trial: avelumab-based combinations as first-line maintenance in advanced urothelial carcinoma.
    Hoffman-Censits J; Grivas P; Powles T; Hawley J; Tyroller K; Seeberger S; Guenther S; Jacob N; Mehr KT; Hahn NM
    Future Oncol; 2024 Feb; 20(4):179-190. PubMed ID: 37671748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial.
    Vignani F; Tambaro R; De Giorgi U; Giannatempo P; Bimbatti D; Carella C; Stellato M; Atzori F; Aieta M; Masini C; Hamzaj A; Ermacora P; Veccia A; Scandurra G; Gamba T; Ignazzi G; Pignata S; Di Napoli M; Lolli C; Procopio G; Pierantoni F; Zonno A; Santini D; Di Maio M;
    Eur Urol; 2023 Jan; 83(1):82-89. PubMed ID: 36216658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice.
    Grivas P; Agarwal N; Pal S; Kalebasty AR; Sridhar SS; Smith J; Devgan G; Sternberg CN; Bellmunt J
    Cancer Treat Rev; 2021 Jun; 97():102187. PubMed ID: 33839438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma.
    Grivas P; Kopyltsov E; Su PJ; Parnis FX; Park SH; Yamamoto Y; Fong PC; Tournigand C; Climent Duran MA; Bamias A; Caserta C; Chang J; Cislo P; di Pietro A; Wang J; Powles T
    Eur Urol; 2023 Apr; 83(4):320-328. PubMed ID: 35654659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma.
    Mansinho A; Cruz A; Marconi L; Pinto C; Augusto I
    Adv Ther; 2023 Oct; 40(10):4134-4150. PubMed ID: 37608243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.
    Yap TA; Bardia A; Dvorkin M; Galsky MD; Beck JT; Wise DR; Karyakin O; Rubovszky G; Kislov N; Rohrberg K; Joy AA; Telli ML; Schram AM; Conte U; Chappey C; Stewart R; Stypinski D; Michelon E; Cesari R; Konstantinopoulos PA
    JAMA Oncol; 2023 Jan; 9(1):40-50. PubMed ID: 36394849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Podcast on Practical Considerations in Patients with Advanced Urothelial Cancer Receiving First-Line Cisplatin- or Carboplatin-Based Chemotherapy Followed by Avelumab Maintenance in a Changing Therapeutic Landscape.
    Gong J; Reimers MA
    Adv Ther; 2024 Sep; 41(9):3441-3451. PubMed ID: 39023740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.
    Grivas P; Park SH; Voog E; Caserta C; Gurney H; Bellmunt J; Kalofonos H; Ullén A; Loriot Y; Sridhar SS; Yamamoto Y; Petrylak DP; Sternberg CN; Gupta S; Huang B; Costa N; Laliberte RJ; di Pietro A; Valderrama BP; Powles T
    Eur Urol; 2023 Jul; 84(1):95-108. PubMed ID: 37121850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis.
    Tomita Y; Yamamoto Y; Tsuchiya N; Kanayama H; Eto M; Miyake H; Powles T; Yoshida M; Koide Y; Umeyama Y; di Pietro A; Uemura H
    Int J Clin Oncol; 2022 Feb; 27(2):383-395. PubMed ID: 34973108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis.
    Apolo AB; Ellerton JA; Infante JR; Agrawal M; Gordon MS; Aljumaily R; Gourdin T; Dirix L; Lee KW; Taylor MH; Schöffski P; Wang D; Ravaud A; Manitz J; Pennock G; Ruisi M; Gulley JL; Patel MR
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cost-effectiveness analysis of avelumab plus best supportive care versus best supportive care alone as first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma in Taiwan.
    Su PJ; Xiao Y; Lin AY; Goh C; Wu E; Liu K; Chou P; Kuo K; Palencia R; Chang J; Kearney M; Kapetanakis V; Benedict A
    Cancer Rep (Hoboken); 2023 Oct; 6(10):e1887. PubMed ID: 37640556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating Real-World Characteristics of Patients With Advanced Urothelial Carcinoma Eligible for Avelumab Maintenance Therapy: A Multicountry Retrospective Medical Chart Review.
    Bellmunt J; Chang J; Pavilack-Kirker M; Cappelleri JC; Costa N; Esterberg E; Kearney M; Hitchens A; Candrilli SD; Ajmera M
    Clin Genitourin Cancer; 2023 Aug; 21(4):459-466. PubMed ID: 37149458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evidence and insights supporting the use of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in the Asia-Pacific region.
    Eto M; Lee JL; Chang YH; Gao S; Singh M; Gurney H
    Asia Pac J Clin Oncol; 2022 Oct; 18(5):e191-e203. PubMed ID: 35238147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Avelumab in locally advanced or metastatic urothelial carcinoma.
    Jackson-Spence F; Szabados B; Toms C; Yang YH; Sng C; Powles T
    Expert Rev Anticancer Ther; 2022 Feb; 22(2):135-140. PubMed ID: 35015593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. J-AVENUE: A retrospective, real-world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first-line maintenance therapy in Japan.
    Kikuchi E; Hayakawa N; Nakayama M; Uno M; Nakatsu H; Kitagawa C; Miyake H; Yamada T; Fujita K; Shimoyama H; Nishihara K; Kobayashi M; Nakamura M; Fujimoto K; Sano T; Nishiyama N; Ito T; Kajita M; Kobayashi T; Kitamura H
    Int J Urol; 2024 Aug; 31(8):859-867. PubMed ID: 38722221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.
    Patel MR; Ellerton J; Infante JR; Agrawal M; Gordon M; Aljumaily R; Britten CD; Dirix L; Lee KW; Taylor M; Schöffski P; Wang D; Ravaud A; Gelb AB; Xiong J; Rosen G; Gulley JL; Apolo AB
    Lancet Oncol; 2018 Jan; 19(1):51-64. PubMed ID: 29217288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance.
    Sridhar SS; Powles T; Climent Durán MÁ; Park SH; Massari F; Thiery-Vuillemin A; Valderrama BP; Ullén A; Tsuchiya N; Aragon-Ching JB; Gupta S; Petrylak DP; Bellmunt J; Wang J; Laliberte RJ; di Pietro A; Costa N; Grivas P; Sternberg CN; Loriot Y
    Eur Urol; 2024 Feb; 85(2):154-163. PubMed ID: 37714742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice.
    Grivas P; Grande E; Davis ID; Moon HH; Grimm MO; Gupta S; Barthélémy P; Thibault C; Guenther S; Hanson S; Sternberg CN
    ESMO Open; 2023 Dec; 8(6):102050. PubMed ID: 37976999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.